Form 4: Edwards Lifesciences Exec Sells Shares Under 10b5-1 Plan

Edwards Lifesciences CVP Donald E. Bobo Jr. exercised options and sold 11,340 shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Donald E. Bobo Jr., CVP, Strategy/Corp Development at Edwards Lifesciences Corp (EW), engaged in transactions involving common stock on December 10, 2025.
• These transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025.
• Bobo exercised employee stock options to acquire 11,340 shares of common stock at an exercise price of $59.2567 per share.
• Concurrently, Bobo sold 11,340 shares of common stock at a weighted average price of $83.8255 per share, with individual trades ranging from $83.465 to $84.100.
• Following these transactions, Bobo directly owns 50,356.3707 shares, and indirectly owns 38,817.6991 shares in a 401(k) and 135,152 shares by Trust.
• 45,360 employee stock options remain beneficially owned by the reporting person.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale reduces direct ownership, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about negative signals. The executive also realized a profit from option exercise, which is a positive for the individual.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information.
• The insider realized a profit by exercising options at $59.2567 and selling shares at a higher weighted average price of $83.8255.

Negatives

• An insider sale, even if pre-planned, reduces the direct equity stake of a key executive.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The sale by an executive, even if pre-planned, slightly reduces insider alignment, but the 10b5-1 plan context minimizes negative interpretation.

Key Dates

Recommendation

The filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged 10b5-1 plan. This type of transaction is generally not considered a strong signal for future stock performance, as it reflects personal financial planning rather than a change in the executive's outlook on the company. Therefore, it does not provide new information that would warrant a change in investment recommendation.

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Donald E. Bobo Jr., 10b5-1 Plan, Corporate Development